tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Promising Developments and Strategic Advancements Propel Gain Therapeutics to ‘Buy’ Rating

Promising Developments and Strategic Advancements Propel Gain Therapeutics to ‘Buy’ Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Gain Therapeutics, retaining the price target of $5.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight Gain Therapeutics’ promising developments and strategic advancements. The company has successfully completed enrollment for its Phase 1b trial of GT-02287 in Parkinson’s disease ahead of schedule, which is a significant milestone. This early completion allows for the anticipation of biomarker data by the fourth quarter of 2025, potentially providing proof of concept for the drug’s efficacy.
GT-02287, an allosteric modulator, has shown encouraging preclinical results, including enhanced enzyme activity and neuroprotection, which supports its potential as a disease-modifying treatment. Furthermore, Gain Therapeutics is well-funded through the Phase 1b data release, which is crucial for its ongoing development plans. The valuation model incorporates a 70% revenue risk adjustment and a 30% discount rate, reflecting the clinical trial risks and development stage, leading to a favorable 12-month price target.

In another report released today, Scotiabank also maintained a Buy rating on the stock with a $12.00 price target.

Disclaimer & DisclosureReport an Issue

1